Self-Adjuvanting Peptide Conjugates via Lipid Linkage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current synthetic peptide vaccines often lack immunogenicity and require external adjuvants like Freund's adjuvant, which can be toxic and complicate vaccine preparation, necessitating the development of self-adjuvanting vaccines that covalently link peptide epitopes with adjuvants for enhanced antigen uptake and immune response.
Innovation Solution
The development of amino acid or peptide conjugates with specific structural formulas that incorporate lipid moieties, allowing for self-adjuvanting properties without the need for external adjuvants, by conjugating fatty acid groups to cysteine residues or other amino acids, enhancing antigen presentation and immune activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If synthetic peptide vaccines are used as sole vaccine components, then the vaccine structure is simple and easy to synthesize, but the immunogenicity is insufficient
Solution Approach 1:
The patent combines peptide epitopes with adjuvant moieties (such as lipid A or lipopolysaccharide) to create a single self-adjuvanting conjugate molecule. This merging eliminates the need for separate adjuvant components while maintaining both the simplicity of synthetic peptide production and the enhanced immunogenicity provided by the adjuvant portion.
Solution Approach 2:
The vaccine comprises a composite structure where a peptide portion (providing antigen specificity) is covalently linked to an adjuvant portion (providing immune stimulation). This composite material approach allows the vaccine to simultaneously exhibit the advantages of simple peptide synthesis and the immunogenicity enhancement of adjuvants.
2Reliability
If external adjuvants like Freund's adjuvant are included in the vaccine, then the immunogenicity is enhanced, but the vaccine preparation becomes complicated and toxic biological by-products are introduced
Solution Approach 1:
By integrating the adjuvant functionality directly into the peptide vaccine molecule through covalent bonding, the patent eliminates the need for separate adjuvant components and complex co-formulation procedures. The self-adjuvanting conjugate requires only straightforward synthesis and purification, removing toxic by-products while simplifying preparation.
Solution Approach 2:
The invention extracts the adjuvant effect from separate external adjuvant components and incorporates it directly into the peptide structure itself. This extraction of the essential immunostimulatory function and its integration into the vaccine molecule eliminates the complications and toxicity associated with external adjuvants.
3Reliability
If self-adjuvanting vaccines with covalently linked peptide epitopes and adjuvants are developed, then the antigen uptake and dendritic cell maturation are enhanced, but the vaccine preparation becomes complicated
Solution Approach 1:
The self-adjuvanting vaccine is designed with distinct functional segments: a peptide epitope portion for antigen recognition and an adjuvant moiety (such as lipid A) for immune stimulation. This segmentation allows each component to perform its specific function while being covalently linked, enhancing antigen uptake and dendritic cell maturation without requiring complex preparation procedures.
Data Source
AI summary
The invention relates to amino acid and peptide conjugates, methods for making amino acid and peptide conjugates, conjugates produced by the methods, and pharmaceutical compositions comprising the conjugates. Methods of eliciting immune responses in a subject and methods of vaccinating a subject, uses of the conjugates for the same, and uses of the conjugates in the manufacture of medicaments for the same are also contemplated.